Over the past 45 years, Mr. Gorlin has founded several biotechnology and pharmaceutical companies, including Hycor Biomedical, Inc. (acquired by Agilent), Theragenics Corporation (NYSE: TGX), CytRx Corporation (NASDAQ: CYTR), Medicis Pharmaceutical Corporation (sold to Valeant for approximately $2.6 billion), EntreMed, Inc. (NASDAQ: ENMD), MRI Interventions (MRIC), DARA BioSciences, Inc. (NASDAQ: DARA), MiMedx (NASDAQ: MDXG), and Medivation, Inc. (NASDAQ: MDVN). Mr. Gorlin served for many years on the Business Advisory Council to the Johns Hopkins School of Medicine and on The Johns Hopkins BioMedical Engineering Advisory Board and serves on the Board of Andrews Institute. Mr. Gorlin founded a number of nonmedical related companies, including Perma-Fix, Inc., Pretty Good Privacy, Inc. (sold to Network Associates), Judicial Correction Services, Inc. (sold to Correctional Healthcare), and NTC China. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children. He presently serves as Vice Chairman of NantKwest, Inc., Chairman of ViCapsys, CEO of Nantibody Fc and on the Boards of Medovex, Inc. (MDVXU), Catasys, Inc. (CATS), Nantibody Fc and on the Board of NTC China, Inc. He is also a member of the Research Institute Advisory Council (RIAC) at Massachusetts General Hospital.
Michael Callahan, MD
Advisor and Chief Medical Officer
Michael is a pioneer of the gene-encoded therapeutics (GET) industry, serving as the DARPA Program Manager that oversaw the development of GET s under the DARPA Advanced Manufacture of Pharmaceuticals and ADEPT-PROTECT programs. He has been billeted for over 8 years at different offices in the FDA (mostly CBER), and serves as a current FDA expert on regenerative medicine. In these capacities he has been able to gain insight into the successes
and failures of GET approaches that inform SmartPharm’s strategy. Michael is currently President of United Therapeutics, Cellular Therapies, where he has advanced two GETs into clinical stages of development (one Ph2 trial and 1 CTA trial). He has overseen 16 INDs, 3 EUA/Orphan applications; a successful orphan voucher for AbbVie, multiple acquisitions (incl. SolvaldiTM; cPG), and 2 drug approvals.
Jon Mogford, PhD
CEO and past Vice Chancellor of Research
Dr. Jon Mogford, has served in various capacities for the Texas A&M University System (“Texas A&M”). Since May 2013, Dr. Mogford has served as the Vice Chancellor for Research, from August 2012 until April 2013 he served as the Chief Research Officer and from November 2011 until August 2012 he served as Associate Vice Chancellor for Strategic Initiatives at Texas A&M. Prior to joining the Texas A&M in 2011, from February 2010 until October 2011, Dr. Mogford served as Deputy Director of the Defense Sciences Office (DSO) of the Defense Advanced Research Projects Agency (DARPA) in the U.S. Department of Defense. From July 2005 until January 2009, Dr. Mogford served as Program Manager of DSO of DARPA. In addition, since November 2016, Dr. Mogford has served as a member of the board of directors of Medovex Corp. Dr. Mogford is the recipient of the Secretary of Defense Medal for Outstanding Public Service. Dr. Mogford obtained his bachelor’s degree in Zoology from Texas A&M University and doctorate in Medical Physiology from the Texas A&M University Health Science Center, College Station, Texas. His research in vascular physiology continued at the University of Chicago as a Postdoctoral fellow from 1997 until 1998. Dr. Mogford transitioned his research focus to the field of wound healing at Northwestern University, both as a Research Associate and also as a Research Assistant Professor from 1998 until 2003. He then served as a Life Sciences Consultant to DARPA on the Revolutionizing Prosthetics program from December 2003 until June 2005. Dr. Mogford is qualified to serve as a member of the Company’s Board because of his experience and research in regenerative medicine.
Stephen J. McCormack, PhD
Dr. McCormack is a serial entrepreneur, and chief executive in the biotechnology and medical device field. He contributed to the development of several medical products and technologies that address unmet medical need. Over the past 20 years, McCormack co-founded and operated several companies including AlleCure, conducting the first clinical studies of intralymphatic immunotherapy, MannKind (NASDAQ:MNKD) with global IND trials in diabetes, cancer vaccines, and allergy. He was part of the founding of CytoMx Therapeutics (NASDAQ: CTMX) developing antibody therapeutics in oncology. He is a member of the Board of Directors of Treatment Research Institute, was previously a Trustee at The Betty Ford Center. He is a member of the President’s Advisory Council of The Albany College of Pharmacy and Health Sciences and is Chairman of the Board of Directors and CEO of Visus Technology. He lived in Europe for four years and was a Managing Director at Global Life Science Ventures in Zug, Switzerland and the Chief Executive Officer of Intelligent Medical Implants (now Pixium Vision, EUR:PIX) leading the CE mark approval across Europe for a retinal prosthetic implant to treat retinitis pigmentosa patients. He currently is currently Chief Scientific Officer of Gorlin Companies as a member of the investment team. McCormack is Chief Executive Officer of ViCapsys, Inc. a company focused on islet cell transplant for the treatment of diabetes. In addition, he is Chief Executive Officer of Aperisys, Inc., a start-up company developing immune activator drugs, vaccines and antibodies for the treatment of cancer.
Jesse Crowne has over 20 years of experience working with rapidly growing health care companies. Most recently, Jesse served as CEO of Arapeen Medical in Salt Lake City, a pre-clinical medical device company focused on developing a magnetic resonance guided focused ultrasound device for the treatment of hypertension, and as VP of Business Development for Medovex Corporation in Atlanta, GA, a clinical stage device company focused on building multiple sales channels in the orthopedic device arena. Prior to Arapeen Medical and Medovex, Mr. Crowne was an Associate with White Pine Medical, a private equity investment vehicle and subsidiary of Essex Woodlands, focused on the medical device sector.
Mr. Crowne received an MBA and an MPH from Westminster College and BS degrees in Biology and Economics from the University of Utah.
Ashley G. Johnson
Since 2002, Mrs. Ashley Johnson, has been instrumental in the successful launches of numerous Gorlin Companies business ventures, including Dara Biosciences, Medivation, MiMedx, Medovex and others. Mrs. Johnson is involved in several charitable organizations including Alaqua Animal Refuge and The Zika Foundation.
Chief of Staff, Gorlin Companies
Justin Lupow is the Chief of Staff for Gorlin Companies, Inc. where he is responsible for overseeing marketing, communication, and investment activities for the entire investment portfolio companies. Mr. Lupow was Director of Philanthropy at The Zika Foundation where he was charged with raising awareness, event coordination and fundraising activities, and served also as a liaison between the Foundation and various stakeholders, including The Centers for Disease Control and Prevention (CDC).
Joseph D. Giglio
Executive Vice President, Chief Operating Officer
Joe is a recognized thought-leader in drug development strategy for emerging oncology therapeutics. Having held executive level positions within several drug development organizations, Mr. Giglio is a seasoned business executive and visionary leader. In 2004, Mr. Giglio co-founded Accrual Solutions, an organization that guided the clinical trial strategy for many National Cancer Institute (NCI) cooperative groups. In 2010, Mr. Giglio co-founded Oncology Trial Insights (OTI), a company composed of more than one-hundred oncology thought-leaders; and which, crafted the scientific strategy for pharmaceutical companies engaged in oncology drug development. During his tenure in the drug development industry, Mr. Giglio has been personally involved with nearly two hundred oncology clinical trials.